Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Sales Revenue, Goods, Net (Deprecated 2018-01-31)

1.8 / 5 stars · 42/120 Roast Me

GILEAD SCIENCES, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)

GILEAD SCIENCES, INC. (GILD) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $5.00 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.

Discontinued › Expense Statement › Operating Expenses

us-gaap:SalesRevenueGoodsNet · last filed 2018-05-09

  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $5.00B, a 21.58% decline year-over-year.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $5.84B, a 19.11% decline year-over-year.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $6.40B, a 13.54% decline year-over-year.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $7.05B, a 7.91% decline year-over-year.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $25.66B, a 14.33% decline from fiscal 2016.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $29.95B, a 6.84% decline from fiscal 2015.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $32.15B, a 31.37% increase from fiscal 2014.
  • GILEAD SCIENCES, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $24.47B, a 126.53% increase from fiscal 2013.
Period endSales Revenue, Goods, Net (Deprecated 2018-01-31) 3 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filedSales Revenue, Goods, Net (Deprecated 2018-01-31) 6 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filedSales Revenue, Goods, Net (Deprecated 2018-01-31) 9 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filedSales Revenue, Goods, Net (Deprecated 2018-01-31) 12 monthSales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed
2018-03-31$5.00B
10-Q · filed 2018-05-09
$10.84B
derived: sum of 2 quarters · filed 2018-05-09
$17.24B
derived: sum of 3 quarters · filed 2018-05-09
$24.29B
derived: sum of 4 quarters · filed 2018-05-09
2017-12-31$5.84B
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$12.24B
derived: sum of 2 quarters · filed 2018-02-27
$19.29B
derived: sum of 3 quarters · filed 2018-02-27
$25.66B
10-K · filed 2018-02-27
2017-09-30$6.40B
10-Q · filed 2017-11-07
$13.45B
derived: sum of 2 quarters · filed 2017-11-07
$19.82B
10-Q · filed 2017-11-07
$27.04B
derived: sum of 4 quarters · filed 2018-05-09
2017-06-30$7.05B
10-Q · filed 2017-08-07
$13.42B
10-Q · filed 2017-08-07
$20.64B
derived: sum of 3 quarters · filed 2018-05-09
$28.04B
derived: sum of 4 quarters · filed 2018-05-09
2017-03-31$6.38B
10-Q · filed 2018-05-09
$13.59B
derived: sum of 2 quarters · filed 2018-05-09
$21.00B
derived: sum of 3 quarters · filed 2018-05-09
$28.65B
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31$7.22B
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$14.62B
derived: sum of 2 quarters · filed 2018-02-27
$22.27B
derived: sum of 3 quarters · filed 2018-02-27
$29.95B
10-K · filed 2018-02-27
2016-09-30$7.41B
10-Q · filed 2017-11-07
$15.06B
derived: sum of 2 quarters · filed 2017-11-07
$22.74B
10-Q · filed 2017-11-07
$31.15B
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$7.65B
10-Q · filed 2017-08-07
$15.33B
10-Q · filed 2017-08-07
$23.74B
derived: sum of 3 quarters · filed 2018-02-27
$31.95B
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$7.68B
10-Q · filed 2017-05-10
$16.09B
derived: sum of 2 quarters · filed 2018-02-27
$24.30B
derived: sum of 3 quarters · filed 2018-02-27
$32.43B
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$8.41B
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$16.62B
derived: sum of 2 quarters · filed 2018-02-27
$24.75B
derived: sum of 3 quarters · filed 2018-02-27
$32.15B
10-K · filed 2018-02-27
2015-09-30$8.21B
10-Q · filed 2016-11-07
$16.34B
derived: sum of 2 quarters · filed 2016-11-07
$23.74B
10-Q · filed 2016-11-07
$30.96B
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30$8.13B
10-Q · filed 2016-08-05
$15.53B
10-Q · filed 2016-08-05
$22.75B
derived: sum of 3 quarters · filed 2017-02-27
$28.72B
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31$7.41B
10-Q · filed 2016-05-06
$14.63B
derived: sum of 2 quarters · filed 2017-02-27
$20.59B
derived: sum of 3 quarters · filed 2017-02-27
$27.01B
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31$7.22B
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$13.19B
derived: sum of 2 quarters · filed 2017-02-27
$19.60B
derived: sum of 3 quarters · filed 2017-02-27
$24.47B
10-K · filed 2017-02-27
2014-09-30$5.97B
10-Q · filed 2015-11-04
$5.97B
10-Q · filed 2014-11-05
$12.38B
derived: sum of 2 quarters · filed 2015-11-04
$17.25B
10-Q · filed 2015-11-04
$17.25B
10-Q · filed 2014-11-05
$20.30B
derived: sum of 4 quarters · filed 2016-02-24
2014-06-30$6.41B
10-Q · filed 2015-08-05
$6.41B
10-Q · filed 2014-08-04
$11.28B
10-Q · filed 2015-08-05
$11.28B
10-Q · filed 2014-08-04
$14.33B
derived: sum of 3 quarters · filed 2016-02-24
$17.04B
derived: sum of 4 quarters · filed 2016-02-24
2014-03-31$4.87B
10-Q · filed 2015-05-08
$4.87B
10-Q · filed 2014-05-07
$7.91B
derived: sum of 2 quarters · filed 2016-02-24
$10.62B
derived: sum of 3 quarters · filed 2016-02-24
$13.28B
derived: sum of 4 quarters · filed 2016-02-24
2013-12-31$3.04B
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24
$5.75B
derived: sum of 2 quarters · filed 2016-02-24
$8.41B
derived: sum of 3 quarters · filed 2016-02-24
$10.80B
10-K · filed 2016-02-24
$10.80B
10-K · filed 2014-02-25
2013-09-30$2.71B
10-Q · filed 2014-11-05
$5.37B
derived: sum of 2 quarters · filed 2014-11-05
$7.76B
10-Q · filed 2014-11-05
$10.27B
derived: sum of 4 quarters · filed 2015-02-25
2013-06-30$2.66B
10-Q · filed 2014-08-04
$5.05B
10-Q · filed 2014-08-04
$7.56B
derived: sum of 3 quarters · filed 2015-02-25
$9.92B
derived: sum of 4 quarters · filed 2015-02-25
2013-03-31$2.39B
10-Q · filed 2014-05-07
$4.90B
derived: sum of 2 quarters · filed 2015-02-25
$7.26B
derived: sum of 3 quarters · filed 2015-02-25
$9.58B
derived: sum of 4 quarters · filed 2015-02-25
2012-12-31$2.51B
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25
$4.87B
derived: sum of 2 quarters · filed 2015-02-25
$7.19B
derived: sum of 3 quarters · filed 2015-02-25
$9.40B
10-K · filed 2015-02-25
$9.40B
10-K · filed 2013-02-27
2012-09-30$2.36B
10-Q · filed 2013-10-31
$4.68B
derived: sum of 2 quarters · filed 2013-10-31
$6.89B
10-Q · filed 2013-10-31
$9.02B
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$2.32B
10-Q · filed 2013-08-01
$4.53B
10-Q · filed 2013-08-01
$6.66B
derived: sum of 3 quarters · filed 2014-02-25
$8.73B
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31$2.21B
10-Q · filed 2013-05-08
$4.34B
derived: sum of 2 quarters · filed 2014-02-25
$6.41B
derived: sum of 3 quarters · filed 2014-02-25
$8.45B
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$2.13B
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
$4.20B
derived: sum of 2 quarters · filed 2014-02-25
$6.24B
derived: sum of 3 quarters · filed 2014-02-25
$8.10B
10-K · filed 2014-02-25
2011-09-30$2.07B
10-Q · filed 2012-11-06
$4.11B
derived: sum of 2 quarters · filed 2012-11-06
$5.97B
10-Q · filed 2012-11-06
$7.90B
derived: sum of 4 quarters · filed 2013-02-27
2011-06-30$2.04B
10-Q · filed 2012-08-01
$3.90B
10-Q · filed 2012-08-01
$5.83B
derived: sum of 3 quarters · filed 2013-02-27
$7.70B
derived: sum of 4 quarters · filed 2013-02-27
2011-03-31$1.86B
10-Q · filed 2012-05-04
$3.79B
derived: sum of 2 quarters · filed 2013-02-27
$5.66B
derived: sum of 3 quarters · filed 2013-02-27
$7.47B
derived: sum of 4 quarters · filed 2013-02-27
2010-12-31$1.93B
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27
$3.80B
derived: sum of 2 quarters · filed 2013-02-27
$5.60B
derived: sum of 3 quarters · filed 2013-02-27
$7.39B
10-K · filed 2013-02-27
2010-09-30$1.87B
10-Q · filed 2011-11-04
$3.67B
derived: sum of 2 quarters · filed 2011-11-04
$5.46B
10-Q · filed 2011-11-04
$7.26B
derived: sum of 4 quarters · filed 2012-02-23
2010-06-30$1.81B
10-Q · filed 2011-08-05
$3.59B
10-Q · filed 2011-08-05
$5.40B
derived: sum of 3 quarters · filed 2012-02-23
$7.05B
derived: sum of 4 quarters · filed 2012-02-23
2010-03-31$1.79B
10-Q · filed 2011-05-09
$3.59B
derived: sum of 2 quarters · filed 2012-02-23
$5.24B
derived: sum of 3 quarters · filed 2012-02-23
$6.81B
derived: sum of 4 quarters · filed 2012-02-23
2009-12-31$1.80B
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23
$3.45B
derived: sum of 2 quarters · filed 2012-02-23
$5.02B
derived: sum of 3 quarters · filed 2012-02-23
$6.47B
10-K · filed 2012-02-23
2009-09-30$1.65B
10-Q · filed 2010-11-08
$3.22B
derived: sum of 2 quarters · filed 2010-11-08
$4.66B
10-Q · filed 2010-11-08
$6.05B
derived: sum of 4 quarters · filed 2011-02-28
2009-06-30$1.57B
10-Q · filed 2010-08-09
$3.02B
10-Q · filed 2010-08-09
$4.40B
derived: sum of 3 quarters · filed 2011-02-28
$5.74B
derived: sum of 4 quarters · filed 2011-02-28
2009-03-31$1.45B
10-Q · filed 2010-05-10
$2.84B
derived: sum of 2 quarters · filed 2011-02-28
$4.17B
derived: sum of 3 quarters · filed 2011-02-28
$5.39B
derived: sum of 4 quarters · filed 2011-02-28
2008-12-31$1.39B
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28
$2.73B
derived: sum of 2 quarters · filed 2011-02-28
$3.94B
derived: sum of 3 quarters · filed 2011-02-28
$5.08B
10-K · filed 2011-02-28
2008-09-30$1.34B
10-Q · filed 2009-11-05
$2.56B
derived: sum of 2 quarters · filed 2009-11-05
$3.70B
10-Q · filed 2009-11-05
2008-06-30$1.22B
10-Q · filed 2009-08-05
$2.36B
10-Q · filed 2009-08-05
2007-12-31$3.73B
10-K · filed 2010-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31